The B-Cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology

Seminars in Hematology

Volumn 51, Issue 3, 2014, Pages 206-218

  Zhong, Yiming ^a   Byrd, John C ^a,b   Dubovsky, Jason A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; AVL 292; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; DASATINIB; DUVELISIB; ENZASTAURIN; FOSTAMATINIB; IBRUTINIB; IDELALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PROTEIN KINASE; PROTEIN KINASE BTK; PROTEIN KINASE LYN; PROTEIN KINASE SYK; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ANEMIA; ARTICLE; B LYMPHOCYTE ACTIVATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHITIS; CANCER IMMUNOLOGY; CELL MATURATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COUGHING; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ECCHYMOSIS; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; HYPERTENSION; INFECTION; LEUKEMIA CELL; LEUKEMOGENESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL EDEMA; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84904412940     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.05.007     Document Type: Article

References (101)

1. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120:1175-1184.
2. Durandy A. Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur J Immunol 2003, 33:2069-2073.
3. Yan C.T., Boboila C., Souza E.K., Franco S., Hickernell T.R., Murphy M., et al. IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 2007, 449:478-482.
4. Stavnezer J., Amemiya C.T. Evolution of isotype switching. Semin Immunol 2004, 16:257-275.
5. Fais F., Ghiotto F., Hashimoto S., Sellars B., Valetto A., Allen S.L., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Investig 1998, 102:1515-1525.
6. Rui L., Schmitz R., Ceribelli M., Staudt L.M. Malignant pirates of the immune system. Nature Immunol 2011, 12:933-940.
7. Tobin G., Thunberg U., Karlsson K., Murray F., Laurell A., Willander K., et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004, 104:2879-2885.
8. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41:599-613.
9. Campbell M.A., Sefton B.M. Association between B-lymphocyte membrane immunoglobulin and multiple members of the Src family of protein tyrosine kinases. Mol Cell Biol 1992, 12:2315-2321.
10. Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T, Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science. 199;251:192-4.
11. Engels N., Wollscheid B., Wienands J. Association of SLP-65/BLNK with the B cell antigen receptor through a non-ITAM tyrosine of Ig-alpha. Eur J Immunol 2001, 31:2126-2134.
12. Wienands J., Engels N. Multitasking of Ig-alpha and Ig-beta to regulate B cell antigen receptor function. Int Rev Immunol 2001, 20:679-696.
13. Kabak S., Skaggs B.J., Gold M.R., Affolter M., West K.L., Foster M.S., et al. The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell antigen receptor to distal signaling pathways. Mol Cell Biol 2002, 22:2524-2535.
14. Fu C., Turck C.W., Kurosaki T., Chan A.C. BLNK: a central linker protein in B cell activation. Immunity 1998, 9:93-103.
15. de Gorter D.J., Vos J.C., Pals S.T., Spaargaren M. The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral. J Immunol 2007, 178:1405-1414.
16. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004, 117:5965-5973.
17. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene 2001, 20:2390-2400.
18. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nature Cell Biol. 200;24:E131-E136.
19. Motiwala T., Zanesi N., Datta J., Roy S., Kutay H., Checovich A.M., et al. AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 2011, 118:6132-6140.
20. Kim Y.J., Sekiya F., Poulin B., Bae Y.S., Rhee S.G. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol 2004, 24:9986-9999.
21. Suzuki-Inoue K., Wilde J.I., Andrews R.K., Auger J.M., Siraganian R.P., Sekiya F., et al. Glycoproteins VI and Ib-IX-V stimulate tyrosine phosphorylation of tyrosine kinase Syk and phospholipase Cgamma2 at distinct sites. Biochem J 2004, 378:1023-1029.
22. Bhattacharyya S., Deb J., Patra A.K., Thuy Pham D.A., Chen W., Vaeth M., et al. NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. J Exp Med 2011, 208:823-839.
23. Macian F., Lopez-Rodriguez C., Rao A. Partners in transcription: NFAT and AP-1. Oncogene 2001, 20:2476-2489.
24. Pham L.V., Tamayo A.T., Yoshimura L.C., Lin-Lee Y.C., Ford Constitutive NF-kappaB and NFAT activation in aggressive B-cell lymphomas synergistically activates the CD154 gene and maintains lymphoma cell survival. Blood 2005, 106:3940-3947.
25. Saijo K., Mecklenbrauker I., Santana A., Leitger M., Schmedt C., Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 2002, 195:1647-1652.
26. Su T.T., Guo B., Kawakami Y., Sommer K., Chae K., Humphries L.A., Kato R.M., et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002, 3:780-786.
27. Kaileh M., Sen R. NF-kappaB function in B lymphocytes. Immunol Rev 2012, 246:254-271.
28. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
29. Malhotra S., Kovats S., Zhang W., Coggeshall K.M. Vav and Rac activation in B cell antigen receptor endocytosis involves Vav recruitment to the adapter protein LAB. J Biol Chem 2009, 284:36202-36212.
30. Dorken B., Moldenhauer G., Pezzutto A., Schwartz R., Feller A., Kiesel S., et al. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986, 136:4470-4479.
31. Wilson G.L., Fox C.H., Fauci A.S., Kehrl J.H. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. J Exp Med 1991, 173:137-146.
32. Kheirallah S., Caron P., Gross E., Quillet-Mary A., Bertrand-Michel J., Fournie J.J., et al. Rituximab inhibits B-cell receptor signaling. Blood 2010, 115:985-994.
33. Lapalombella R., Yeh Y.Y., Wang L., Ramanunni A., Rafiq S., Jha S., et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012, 21:694-708.
34. Justement L.B., Campbell K.S., Chien N.C., Cambier J.C. Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science 1991, 252:1839-1842.
35. Katagiri T., Ogimoto M., Hasegawa K., Mizuno K., Yakura H. Selective regulation of Lyn tyrosine kinase by CD45 in immature B cells. J Biol Chem 1995, 270:27987-27990.
36. Katagiri T., Ogimoto M., Hasegawa K., Arimura Y., Mitomo K., Okada M., Clark M.R., et al. CD45 negatively regulates lyn activity by dephosphorylating both positive and negative regulatory tyrosine residues in immature B cells. J Immunol 1999, 163:1321-1326.
37. Yanagi S., Sugawara H., Kurosaki M., Sabe H., Yamamura H., Kurosaki T., et al. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cells. J Biol Chem 1996, 271:30487-30492.
38. Lam K.P., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
39. Fuentes-Panana E.M., Bannish G., Shah N., Monroe J.G. Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol 2004, 173:1000-1011.
40. Juszczynski P., Chen L., O'Donnell E., Polo J.M., Ranuncolo S.M., Dalla-Favera R., et al. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 2009, 114:5315-5321.
41. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004, 117:787-800.
42. Monroe J.G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006, 6:283-294.
43. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
44. Cornall R.J., Cyster J.G., Hibbs M.L., Dunn A.R., Otipoby K.L., Clark E.A., Goodnow C.C. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998, 8:497-508.
45. Chen L., Juszczynski P., Takeyama K., Aguiar R.C., Shipp M.A. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006, 108:3428-3433.
46. Duhren-von Minden M., Ubelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
47. Binder M., Muller F., Frick M., Wehr C., Simon F., Leistler B., et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood 2013, 121:239-241.
48. Messmer B.T., Albesiano E., Efremov D.G., Ghiotto F., Allen S.L., Kolitz J., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004, 200:519-525.
49. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
50. Seiler T., Woelfle M., Yancopoulos S., Catera R., Li W., Hatzi K., et al. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood 2009, 114:3615-3624.
51. Chu C.C., Catera R., Zhang L., Didier S., Agagnina B.M., Damle R.N., et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010, 115:3907-3915.
52. Rosen A., Murray F., Evaldsson C., Rosenquist R. Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis. Semin Cancer Biol 2010, 20:400-409.
53. Herishanu Y., Perez-Galan P., Liu D., Biancotto A., Pittaluga S., Vire B., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
54. Herishanu Y., Katz B.Z., Lipsky A., Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013, 27:173-206.
55. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
56. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
57. Chen L., Apgar J., Huynh L., Dicker F., Giago-McGahan T., Rassenti L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105:2036-2041.
58. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007, 104:13283-13288.
59. Amrein P.C. The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. Leuk Lymphoma 2011, 52:754-763.
60. Amrein P.C., Attar E.C., Takvorian T., Hochberg E.P., Ballen K.K., Leahy K.M., et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011, 17:2977-2986.
61. Kater A.P., Spiering M., Liu R.D., Beckers M.M., Tonino S.H., Daenen S.M.G.J., et al. The broad kinase inhibitor dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter Phase 2 study. ASH Annual Meeting Abstracts 2012, 120:1798.
62. William B.M., Hohenstein M., Loberiza FR, Caponetti G.C., Bociek R.G., Bierman P., et al. Phase I/II study of dasatinib in relapsed or refractory non-Hodgkin[U+05F3]s lymphoma (NHL). ASH Annual Meeting Abstracts 2010, 116:288.
63. Suljagic M., Longo P.G., Bennardo S., Perlas E., Leone G., Laurenti L., et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116:4894-4905.
64. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
65. Quiroga M.P., Balakrishnan K., Kurtova A.V., Sivina M., Keating M.J., Wierda W.G., et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114:1029-1037.
66. Baracho G.V., Miletic A.V., Omori S.A., Cato M.H., Rickert R.C. Emergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiation. Curr Opin Immunol 2011, 23:178-183.
67. Coutre S., Byrd J., Furman R., Brown J., Benson D., Wagner-Johnston N., et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Annual Meeting Abstracts 2011, 29.
68. Furman R.R., Byrd J.C., Brown J.R., Coutre S.E., Benson DM, Wagner-Johnston N.D., et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2010, 116:55.
69. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
70. Benson D.M., Kahl B.S., Furman R.R., Brown J.R., Wagner-Johnston N.D., Coutre S.E., et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3K{delta}, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). ASCO Meeting Abstracts 2013, 31:8526.
71. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1007.
72. O'Brien S.M., Lamanna N., Kipps T.J., Flinn I., Zelenetz A.D., Burger J.A., et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3K{delta}) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) >=65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ASCO Meeting Abstracts 2013, 31:7005.
73. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
74. Eradat H., Coutre S., Rai K., Farber C., Hillmen P., Sharman J., et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). ASCO Annual Meeting Abstracts 2013, 31.
75. Wagner-Johnston N.D., De Vos S., Leonard J., Sharman J.P., Schreeder M.T., Boccia R.V., et al. Preliminary results of PI3K{delta} inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). ASCO Meeting Abstracts 2013, 31:8501.
76. Fowler N., Sharman J.P., Smith S.M., Boyd T., Grant B., Kolibaba K.S., et al. The Btk Inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory b-cell malignancies: results from a Phase I study. ASH Annual Meeting Abstracts 2010, 116:964.
77. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
78. O'Brien S., Furman R.R., Coutre S.E., Sharman J.P., Burger J.A., Blum K.A., et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014, 15:48-58.
79. Keating M.J., Wierda W.G., Hoellenriegel J., Jeyakumar G., Ferrajoli A., Faderl S.H., et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a Phase II trial in 40 patients. Blood 2013, 122:675.
80. Jaglowski S.M., Jones J.A., Flynn J.M., Andritsos L.A., Maddocks K.J., Blum K.A., et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts 2012, 30:6508.
81. Barrientos J.C., Barr P.M., Flinn I., Burger J.A., Salman Z., Clow F., et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL: final results of a Phase 1b study. Blood 2013, 122:525.
82. Dubovsky J.A., Beckwith K.A., Natarajan G., Woyach J.A., Jaglowski S., Zhong Y., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes. Blood 2013, 122:3308-3316.
83. Evans E., Tester R., Aslanian S., Chaturvedi P., Mazdiyasni H., Ponader S., et al. Clinical development of AVL-292; a potent, selective covalent Btk Inhibitor for the treatment of B cell malignancies. ASH Annual Meeting Abstracts 2011, 118:3485.
84. Brown J.R., Sharman J.P., Harb W.A., Kelly K.R., Schreeder M.T., Sweetenham J.W., et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton[U+05F3]s tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstracts 2012, 30:8032.
85. Westlin W., Kathryn S., Lounsbury H., Witowski S., Silver B., Freed M., et al. Translational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton[U+05F3]s tyrosine kinase, in a phase 1b clinical trial. AACR Annual Meeting Abstracts 2012, 72.
86. Robak T., Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 2012, 21:921-947.
87. Dunbar J., Nevejans J., McKee C., Faia K., van Lier J.J., Pruim P., et al. Pharmacokinetics and pharmacodynamics of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, following single- and multiple-dose administration in healthy subjects and patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts 2012, 120:4853.
88. Flinn I.W., Horwitz S.M., Patel M., Younes A., Porter J.R., Sweeney J., et al. Clinical safety and activity in a phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-{delta},{gamma}, in patients with advanced hematologic malignancies. ASH Annual Meeting Abstracts 2012, 120:3663.
89. Peluso M., Fu M., Rosin N.Y., Burger J.A., Wierda W.G., Keating M.J., et al. Inhibition of PI3K-δ and -γ Isoforms by IPI-145 in chronic lymphocytic leukemia overcomes signals from PI3K/AKT/S6 pathway and promotes apoptosis. Blood 2013, 122:4167.
90. Douglas M., Allison K., Ted S., Allen K., Kahl B.S., Horwitz S.M., et al. Treatment with the potent PI3K-δ, γ inhibitor IPI-145 is associated with rapid decreases in specific cytokines, chemokines and matrix metalloproteinases in the serum of patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Blood 2013, 122:1633.
91. Willey C.D., Xiao D., Tu T., Kim K.W., Moretti L., Niermann K.J., et al. Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation. Int J Radiat Oncol Biol Phys 2010, 77:1518-1526.
92. Lee K.W., Kim S.G., Kim H.P., Kwon E., You J., Choi H.J., et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008, 68:1916-1926.
93. Mukohara T., Nagai S., Koshiji M., Yoshizawa K., Minami H. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors. Cancer Sci 2010, 101:2193-2199.
94. Morschhauser F., Seymour J.F., Kluin-Nelemans H.C., Grigg A., Wolf M., Pfreundschuh M., et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008, 19:247-253.
95. Schwartzberg L., Hermann R., Flinn I.W., Flora D., Hsi E.D., Hamid O., et al. Phase II study of enzastaurin in patients with follicular lymphoma: updated final clinical results and immunohistochemical correlations. ASH Annual Meeting Abstracts 2012, 120:777.
96. de Rooij M.F., Kuil A., Geest C.R., Eldering E., Chang B.Y., Buggy J.J., Pals S.T., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
97. Chang B.Y., Francesco M., De Rooij M.F., Magadala P., Steggerda S.M., Huang M.M., et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013, 122:2412-2414.
98. Dubovsky J.A., Chappell D.L., Harrington B.K., Agrawal K., Adritsos L., Flynn J., et al. Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Blood 2013.
99. Jones S.L., Wang J., Turck C.W., Brown E.J. A role for the actin-bundling protein L-plastin in the regulation of leukocyte integrin function. Proc Natl Acad Sci U S A 1998, 95:9331-9336.
100. Morley S.C. The actin-bundling protein L-plastin: a critical regulator of immune cell function. Int J Cell Biol 2012, 2012:935173.
101. Chang B.Y., Furman R.R., Zapatka M., Barrientos J.C., Li D., Steggerda S., et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). ASCO Meeting Abstracts 2013, 31:7014.